{"id":"W2052076354","doi":"10.1007/s10637-013-9931-1","title":"A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Tolerability; Internal medicine; Sunitinib; Clinical endpoint; Renal cell carcinoma; Progressive disease; Phases of clinical research; Pazopanib; Oncology; Adverse effect; Gastroenterology; Clinical trial; Surgery; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001471626,0.001177903,0.001488202,0.0003830779,0.0003513976,0.0007726428,0.0009050196,0.0009521985,0.003109514],"category_scores_gemma":[0.001116369,0.0004291782,0.0009509325,0.0003547734,0.0006904957,0.0005878556,0.0002970018,0.002859671,0.0006563137],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007265775,"about_ca_system_score_gemma":0.00120384,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001389327,"about_ca_topic_score_gemma":0.003907009,"domain_scores_codex":[0.9995951,0.0002465911,0.0000131643,0.00004629846,0.00003657292,0.00006228731],"domain_scores_gemma":[0.9993415,0.000153823,0.0001021767,0.00005774738,0.00003071412,0.0003138876],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7318078,0.05498347,0.009069496,0.0008677313,0.00247181,0.0005305759,0.0002831515,0.003723381,0.03571662,0.0005813842,0.01137135,0.1485932],"study_design_scores_gemma":[0.7994143,0.1774204,0.01401885,0.00002733214,0.0005913679,0.0003773697,0.00004682754,0.001554155,0.002681268,0.0002713733,0.003563717,0.00003311396],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901016,0.003109655,0.0004101121,0.0007188905,0.0001907844,0.001164432,0.001125926,0.00008265241,0.003096077],"genre_scores_gemma":[0.9861982,0.002974094,0.001485797,0.001304429,0.0002300861,0.001097912,0.003339053,0.00003481434,0.003335637],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003109514,"threshold_uncertainty_score":0.01040238,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03995789522017983,"score_gpt":0.3047918596194014,"score_spread":0.2648339643992216,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}